Form 8-K Replimune Group, Inc. For: Jul 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- S&P 500 ends higher as investors await tech earnings
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Barclays Downgrades Replimune Group (REPL) to Equalweight
July 22, 2025 4:31 PM EDTBarclays analyst Peter Lawson downgraded Replimune Group (NASDAQ: REPL) from Overweight to Equalweight with a price target of $3.00 (from $17.00).
The analyst comments "Downgrade to Equal Weight and lower PT to $3 following the surprising CRL issued by FDA for RP1+PD1 combo, which places... More
Leerink Partners Reiterates Outperform Rating on Replimune Group (REPL), PT $21, 'Estimates Under Review'
July 22, 2025 10:20 AM EDTLeerink Partners analyst Jonathan Chang reiterated an Outperform rating and $21.00 price target on Replimune Group (NASDAQ: REPL)
The analyst comments "Bottom Line: The FDA has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec; GALV, GM-CSF oncolytic virus) + nivolumab in anti-PD-1-failed melanoma. This update will likely come as a... More
Mizuho Desk Comments on Replimune (REPL)
July 22, 2025 8:52 AM EDTMizuho Desk Comments on Replimune (NASDAQ: REPL)
The analyst comments "REPL. Stock clobbered on CRL. This came up a few times last month at investor meetings on unfavorable risk/reward into the PDUFA. Playing out nicely this morning for those... More
Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
July 22, 2025 8:50 AM EDTBarclays analyst Peter Lawson reiterated an Overweight rating and $17.00 price target on Replimune Group (NASDAQ: REPL).
The analyst comments "FDA issued a CRL for Replimune's BLA for RP1 in combo with nivo for PD1-refractory melanoma patients. While no safety concerns were raised, FDA cited issues around trial design and evidence of efficacy. This represents a positive read through to Iovance (IOVA, OW) with reduced competitive threat. Our key takeaways from Replimune's... More
